Health Care • Biotechnology: Pharmaceutical Preparations
$2.54 ▼ -0.07
(-2.68%)
MKT CAP: $3.9M • VOL: 50.2K
52W L $2 52W H $434
ROARABLE / RQD
D- • 35/100
PIOTROSKI
3 / 9
ENLV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$15.0M | -$15.9M | -$29.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $1.24B | -$15.0M | -$29.1M |
| EBITDA (Normalized) | -$15.0M | -$15.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.4M | -$13.0M | -$23.5M |
| Capital Expenditures (CapEx) | $68.0K | $103.0K | — |
| Free Cash Flow (FCF) | -$10.5M | -$13.1M | -$23.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -0.6% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.9M | $3.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.93B | $23.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ENLV.